^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    10h
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial • IO biomarker
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Nailike (olverembatinib) • fludarabine IV
    11h
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | N=79 --> 53
    Enrollment change
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    13h
    Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV
    14h
    BHCT-RD06-04: Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov)
    P1, N=20, Recruiting, Nanjing Bioheng Biotech Co., Ltd. | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    15h
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    17h
    Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
    New P1 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    cyclophosphamide • fludarabine IV
    1d
    Nonmyeloablative Conditioning Combined with Anti-CD117 Antibody Briquilimab in Older Adults with High-Risk AML and MDS. (PubMed, Blood)
    Based on preclinical data demonstrating the antibody clears hematopoietic stem and progenitor cells (HSPC) and myeloid malignant cells, we conducted a phase 1 trial examining briquilimab plus non-myeloablative fludarabine (flu) and total body irradiation (TBI) as conditioning for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing matched donor allogeneic hematopoietic cell transplantation (HCT)...Graft-versus-host disease prophylaxis consisted of tacrolimus, sirolimus, and mycophenolate mofetil...In summary, we demonstrate the feasibility, safety, and proof of concept of CD117 targeting with briquilimab as HCT conditioning for AML/MDS. The trial is registered at clinicaltrials.gov; using identifier: NCT04429191.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    sirolimus • fludarabine IV • briquilimab (JSP191)
    1d
    CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children (clinicaltrials.gov)
    P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV
    1d
    PKBMT: Precision Dosing of Anti-Cancer Medicines for patients undergoing Oncology, Blood Transplant and Cellular Therapies. (ACTRN12626000285358)
    P=N/A, N=300, Not yet recruiting, The Children's Hospital at Westmead
    New trial
    |
    fludarabine IV • Grafapex (treosulfan)
    1d
    TUNINTIL-2: TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • igrelimogene litadenorepvec (TILT-123)
    1d
    KarMMa-9: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=79, Active, not recruiting, Celgene | N=618 --> 79 | Trial completion date: Aug 2025 --> Nov 2029
    Enrollment change • Trial completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)
    2d
    A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, Juventas Cell Therapy Ltd. | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Mar 2025
    Enrollment open • Trial initiation date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)